Scarica l'app Stockscreener
7.14
2.46%
-0.18
Dopo l'orario di chiusura:
7.09
-0.05
-0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$7.32
Aprire:
$7.41
Volume 24 ore:
2.52M
Relative Volume:
1.29
Capitalizzazione di mercato:
$794.40M
Reddito:
$24.30M
Utile/perdita netta:
$-145.57M
Rapporto P/E:
-5.3684
EPS:
-1.33
Flusso di cassa netto:
$-149.17M
1 W Prestazione:
-7.99%
1M Prestazione:
+12.26%
6M Prestazione:
+451.35%
1 anno Prestazione:
+9.01%
Intervallo 1D:
$7.12
$7.65
Intervallo di 1 settimana:
$6.78
$7.90
Portata 52W:
$1.03
$8.80
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta TNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
7.14 | 814.43M | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Best data tools to analyze Tango Therapeutics Inc. stockWeekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Tango Therapeutics Inc. stock trendline breakdownIPO Watch & Reliable Entry Point Alerts - newser.com
Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock? - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $10.50 Average PT from Analysts - Defense World
Will Tango Therapeutics Inc. benefit from macro trendsChart Signals & Reliable Price Action Trade Plans - newser.com
Is a relief rally coming for Tango Therapeutics Inc. holders2025 Market Overview & Fast Moving Trade Plans - newser.com
Market reaction to Tango Therapeutics Inc.’s recent newsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
Real time alert setup for Tango Therapeutics Inc. performance2025 Major Catalysts & Safe Capital Growth Plans - newser.com
Tango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss Ratings - MarketBeat
Detecting price anomalies in Tango Therapeutics Inc. with AIJuly 2025 Patterns & Smart Swing Trading Techniques - newser.com
Historical volatility pattern of Tango Therapeutics Inc. visualizedMarket Activity Summary & Fast Moving Market Watchlists - newser.com
Real time social sentiment graph for Tango Therapeutics Inc.Earnings Growth Summary & Daily Entry Point Trade Alerts - newser.com
Tango To Present At The 2025 SITC Annual Meeting — Will New Insights Make Waves? - RTTNews
Regression analysis insights on Tango Therapeutics Inc. performanceTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Is Tango Therapeutics Inc. building a consolidation base2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials By Investing.com - Investing.com South Africa
Tango Therapeutics’ SWOT analysis: biotech stock’s promise amid clinical trials - Investing.com UK
Tango Therapeutics to Present First Clinical Data from - GlobeNewswire
First clinical data: TNG260 — Tango Therapeutics presents Phase 1/2 results at SITC Nov 7 - Stock Titan
Building trade automation scripts for Tango Therapeutics Inc.Weekly Stock Analysis & Daily Growth Stock Investment Tips - newser.com
Published on: 2025-10-05 03:22:51 - newser.com
Piper Sandler Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $11 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Multi factor analysis applied to Tango Therapeutics Inc.Bull Run & Fast Momentum Entry Tips - newser.com
How to use Fibonacci retracement on Tango Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Tango Therapeutics Hits New 52-Week High of $8.79, Marking Major Milestone - Markets Mojo
Healthcare veteran David Wilkinson to join Tango as chief financial officer - MarketScreener
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
Published on: 2025-09-30 04:30:06 - newser.com
Published on: 2025-09-30 03:51:20 - newser.com
Major Shareholder Sells Off Tango Therapeutics Stock in Multi-Million Dollar Deal! - TipRanks
Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 500,000 Shares - MarketBeat
Tango Therapeutics, Inc. $TNGX Position Reduced by Goldman Sachs Group Inc. - Defense World
Tango Therapeutics Hits New 52-Week High at $8.56 - Markets Mojo
Published on: 2025-09-28 23:18:47 - newser.com
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):